Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The efficiency and effectiveness of target selection and validation could be improved with accessible, standardized and integrated biological reference data sets. Such resources should be established through precompetitive approaches.
Grabowski and colleagues analyse the European market uptake of biosimilar versions of two major therapeutic biologics — epoetin alfa and filgrastim — and discuss the implications for the future development of the market for biosimilars.